Premium
OUTREACH: PRELIMINARY SAFETY & EFFICACY RESULTS FROM A PHASE 2 STUDY OF LISOCABTAGENE MARALEUCEL (LISO‐CEL) IN THE NONUNIVERSITY SETTING
Author(s) -
Godwin J. E.,
Mattar B.,
Maris M.,
Bachier C.,
Stevens D. A.,
Hoda D.,
Varela J. C.,
Cherry M.,
Fanning S.,
Essell J.,
Yimer H.,
Courtright J.,
Sharman J.,
Trede N. S.,
Youssef M.,
Lymp J.,
Shaughnessy P.
Publication year - 2021
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.185_2880
Subject(s) - medicine , cytokine release syndrome , adverse effect , leukapheresis , phases of clinical research , clinical endpoint , surgery , chimeric antigen receptor , toxicity , immunotherapy , clinical trial , cancer , stem cell , biology , cd34 , genetics